There has been a growing interest in the use of B cells for cancer vaccines, since they have
yielded promising results in preclinical animal models. Contrary to dendritic cells (DCs), we …

Abstract CD40-activated B cells (CD40-B cells) have previously been introduced as an
alternative source of antigen-presenting cells for immunotherapy. CD40-B cells can prime …

CD40-activated B cells (CD40-B cells) have been identified as an alternative source of
immuno-stimulatory antigen-presenting cells (APC) for cancer immunotherapy 1-3 …

Research on B cells has shown that CD40 activation improves their antigen presentation
capacity. When stimulated with interleukin-4 and CD40 ligand (CD40L), human B cells can …

To date, molecular targets chosen for Ab activation to generate antitumor effector cells have
been confined on T cells, such as TCR/CD3, CD28, CD137 (4-1BB), CD134 (OX40), and …

CD40 engagement is the major signal that induces B cells to efficiently present antigen to T
cells. We previously demonstrated that human peripheral blood–derived CD40-activated B …

The in vivo persistence of adoptively transferred T cells is predictive of antitumor response.
Identifying functional properties of infused T cells that lead to in vivo persistence and tumor …

Immune evasion by tumors includes several different mechanisms, including the inefficiency
of antigen presenting cells (APCs) to trigger anti-tumor T cell responses. B lymphocytes may …

There has been growing interest in the role of B cells in antitumour immunity and potential
use in adoptive cellular therapies. To date, the success of such therapies is limited. The …

Tolerogenic dendritic cells in the tumor microenvironment can inhibit the generation and
maintenance of robust antitumor T cell responses. In this study, we investigated the effects of …